NEW YORK, June 15, 2026 /PRNewswire/ -- Expert Consumers has released a new in depth review highlighting Experian Boost® and its role in helping people...
Newly Launched UniC AG440 and PR-S3 Elite to Provide Full-Scenario Energy Storage Across C&l and Residential ApplicationsMUNICH, June 15, 2026 /PRNewswire/ -- Ampace, a...
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
Marking a new brand transformation milestone in Chow Tai Fook's ongoing international expansion and luxury retail positioningVANCOUVER, BC, June 15, 2026 /CNW/ -- Chow...
This 20,000 sq. ft. facility will redefine fitness standards in Jagatpura, which is the fastest-growing urban hub in JaipurJAIPUR, India, June 14, 2026 /PRNewswire/...
ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.
WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of BitGo Holdings, Inc. (NYSE: BTGO): (i) Class A common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Offering Documents”) issued in connection with BitGo's January 22, 2026 initial public offering ("IPO"); and/or (ii) securities between January 22, 2026 and May 13, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026.
Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...
Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...
Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...
TEL AVIV, Israel, June 14, 2026 (GLOBE NEWSWIRE) -- Orbs, the decentralized Layer-3 blockchain infrastructure focused on advanced on-chain trading, today announced Orbs Institutional, a new offering that provides trading desks, OTC firms, treasuries, custodians and financial platforms with direct access to its on-chain execution infrastructure.